Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemtuzumab Ozogamicin + GCLAM in Untreated AML
NCT03531918Phase 2Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Sep 2018
- Primary completion
- Jul 2021
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemtuzumab ozogamicin in acute myeloid leukemia (AML) and myeloid neoplasm, sponsored by Fred Hutchinson Cancer Center. Primary endpoints: Maximum Tolerated Dose at 1 month and Event-free Survival Rate at 1 year. Started Sep 2018; status: completed.
02
Drugs
gemtuzumab ozogamicin
03
Conditions
acute myeloid leukemia (AML)myeloid neoplasm
Beyond the preview
Go deeper on NCT03531918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03531918.